Jounce Therapeutics, Inc. (JNCE)

NASDAQ: JNCE · IEX Real-Time Price · USD
4.59
0.23 (5.28%)
At close: May 16, 2022 4:00 PM
4.37
-0.22 (-4.79%)
After-hours:May 16, 2022 5:13 PM EDT
Market Cap237.19M
Revenue (ttm)25.37M
Net Income (ttm)-101.70M
Shares Out51.67M
EPS (ttm)-1.82
PE Ration/a
Forward PE19.46
Dividendn/a
Ex-Dividend Daten/a
Volume164,837
Open4.33
Previous Close4.36
Day's Range4.29 - 4.64
52-Week Range4.06 - 9.81
Beta1.03
AnalystsBuy
Price Target16.61 (+261.9%)
Earnings DateMay 5, 2022

About JNCE

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811...

IndustryBiotechnology
IPO DateJan 27, 2017
CEORichard Murray
Employees137
Stock ExchangeNASDAQ
Ticker SymbolJNCE
Full Company Profile

Financial Performance

In 2021, JNCE's revenue was $26.91 million, a decrease of -56.84% compared to the previous year's $62.34 million. Losses were -$90.87 million, 107.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for JNCE stock is "Buy." The 12-month stock price forecast is 16.61, which is an increase of 261.87% from the latest price.

Price Target
$16.61
(261.87% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Jounce Therapeutics Reports First Quarter 2022 Financial Results

- Two combination cohorts met initial response criteria for continued expansion in INNATE trial of JTX-8064; on track to present data on at least 60 Phase 2 patients across multiple cohorts in 2H2022 -

1 week ago - GlobeNewsWire

Jounce Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022

CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...

2 weeks ago - GlobeNewsWire

Jounce Therapeutics to Participate in Raymond James LILRB/ILT Symposium: Deep Dive into “Myeloid Checkpoint” Therapeu...

CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...

3 weeks ago - GlobeNewsWire

Jounce Therapeutics, Inc. (JNCE) Reports Q4 Loss, Lags Revenue Estimates

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -156.52% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st...

2 months ago - Zacks Investment Research

Jounce Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

- Continued execution on two proof-of-concept clinical trials for JTX-8064 and Vopratelimab, INNATE and SELECT, with clinical data on track for 2022 -

2 months ago - GlobeNewsWire

Jounce Therapeutics to Participate in Cowen & Co. 42nd Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

2 months ago - GlobeNewsWire

Jounce Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Wedne...

CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

2 months ago - GlobeNewsWire

Analysts Estimate Jounce Therapeutics, Inc. (JNCE) to Report a Decline in Earnings: What to Look Out for

Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Jounce Therapeutics to Present at Upcoming Investor Conferences in January

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

4 months ago - GlobeNewsWire

Jounce Therapeutics to Present at Upcoming Investor Conferences in November

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

6 months ago - GlobeNewsWire

Jounce Therapeutics, Inc. (JNCE) Reports Q3 Loss, Lags Revenue Estimates

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -47.50% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...

6 months ago - Zacks Investment Research

Jounce Therapeutics Reports Third Quarter 2021 Financial Results

- Commenced enrollment in tumor-specific monotherapy and pimivalimab combination expansion cohorts of INNATE trial of JTX-8064 -

6 months ago - GlobeNewsWire

Jounce Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, ...

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

6 months ago - GlobeNewsWire

Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inh...

- Enrollment initiated in tumor-specific monotherapy and pimivalimab combination expansion cohorts –

7 months ago - GlobeNewsWire

Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors

CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...

8 months ago - GlobeNewsWire

Jounce Therapeutics to Present at Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...

8 months ago - GlobeNewsWire

Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 78.95% and 167.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Jounce Therapeutics Reports Second Quarter 2021 Financial Results

- INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter 2021-

9 months ago - GlobeNewsWire

Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August ...

CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

9 months ago - GlobeNewsWire

Jounce Therapeutics to Participate in William Blair's Biotech Focus Conference

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

10 months ago - GlobeNewsWire

Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update...

- INNATE study rapidly advancing; updates to be provided on enrollment status and receptor occupancy; expansion cohorts expected to open for enrollment in third quarter of 2021-

10 months ago - GlobeNewsWire

Why Jounce Therapeutics Bounced Higher Today

The company gets a regulatory nod that will put $25 million in its pocket.

11 months ago - The Motley Fool

Jounce Therapeutics Stock Is Trading After $25M In Milestone Payment From Gilead

The FDA has signed off Jounce Therapeutics Inc's (NASDAQ: JNCE) Investigational New Drug (IND) application for JTX-1811, triggering a milestone payment of $25 million from Gilead Sciences Inc (NASDAQ: G...

Other symbols:GILD
11 months ago - Benzinga

Jounce Therapeutics to Participate in Fireside Chat at the Raymond James Human Health Innovation Conference

CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...

11 months ago - GlobeNewsWire

Jounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinical Trials at the 2021 American ...

- INNATE trial to include proof-of-concept expansion cohorts in lung, renal, head and neck, triple negative breast, cutaneous squamous cell, and ovarian cancers and soft tissue sarcomas -

11 months ago - GlobeNewsWire